Dr Reddys gets USFDA EIR for Duvvada facilities
Hyderabad: Pharma major, Dr Reddy's Labs, today announced that the company has received the Establishment Inspection Report (EIR) from the U.S Food and Drug Administration (USFDA) for its formulations manufacturing facilities (FTO 7 & FTO 9) at Duvvada, Visakhapatnam, indicating closure of the inspection.
Establishment Inspection Report means the closure of inspection.
"Further to our intimation dated October 29, 2021, on the audit conducted by the USFDA at our formulations manufacturing facilities (FTO 7 & FTO 9) at Duvvada, Visakhapatnam, we wish to inform you that the Company has received the Establishment Inspection Report (EIR) from the USFDA indicating closure of the inspection," the company stated in a BSE filing.
In October, Dr Reddys had got 8 observations from the USFDA after the conclusion of the audit at its formulations manufacturing facilities (FTO 7 & FTO 9) at Duwada, Visakhapatnam.
Read also: Dr Reddy's Labs Gets 8 USFDA Observations For Duwada Facilities
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
Dr. Reddy's operates in markets across the globe. The company's major markets include - USA, India, Russia & CIS countries, and Europe.
Read also: Dr Reddys, Binnopharm ink pact for 2 anti-bacterial brands for Russian region
In yet another news for the day, Dr. Reddy's Labs has joined hands with Binnopharm Group via its affiliate Joint Stock Company 'Alium' that will allow Binnopharm Group to acquire anti-bacterial medicines under the Ciprolet and Levolet brands from Dr. Reddy's in Russia, Uzbekistan and Belarus.
Read also: Dr Reddys, Binnopharm Ink Pact For 2 Anti-Bacterial Brands For Russian Region
